1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-N'-methyl-1,2,4-triazole-3-carboximidamide

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 三唑核糖核苷和核糖核苷酸
• 英文名称: 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-N'-methyl-1,2,4-triazole-3-carboximidamide
• 化学式: C₉H₁₅N₅O₄
• 分子量: 257.25
• InChiKey: BDCXWKXMJHDZGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Nucleoside analogs with carboxamidine modified monocyclic base
  申请人：Ribapharm, Inc.

  公开号：EP1813278A1

  公开（公告）日：2007-08-01

  The inventions relates to the use of the carboxamidine of Formula 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a Hepatitis C Virus (HCV) viral infection or a Hepatitis B Virus (HBV) viral infection, wherein the compound is in L-configuration or D-configuration.

  本发明涉及使用式 1 的羧脒或其药学上可接受的盐制造治疗丙型肝炎病毒（HCV）病毒感染或乙型肝炎病毒（HBV）病毒感染的药物、 其中化合物为 L-构型或 D-构型。
• NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE
  申请人：Tam Robert

  公开号：US20090176721A1

  公开（公告）日：2009-07-09

  Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.